IN THIS ISSUE

Ed Silverman
The health plan was listing badly when Charles Baker boarded it in 2000. Since then, the ship has been righted and the way is clear.
Alice G. Gosfield, JD
Pay-for-performance (P4P) programs promise a fair shake for provider and plan, but a former chairman of the NCQA sees many design flaws to overcome.
Q&A
The physician-author of “Overdosed America” says that health plans have a logical role in actively assessing the medical literature.
Martin Sipkoff
A federal agency fashioned to oversee drug research might inhibit the creation of new medications. The quest for profit in itself may generate benefit.
Legislation & Regulation
John Carroll
The $50 million needed for regional collaborations was not part of the federal government's budget. Not the end of the world, but not good either.
Tomorrow's Medicine
Thomas Morrow, MD
Natalizumab has received FDA approval. But as with all approved treatments, questions remain about efficacy and clinical importance compared to existing therapies.
News and Commentary